The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes

Leukemia and Lymphoma

Volumn 48, Issue 1, 2007, Pages 9-15

  Bhatia, Monica ^a   Davenport, Virginia ^a   Cairo, Mitchell ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 11; PLACEBO; RECOMBINANT INTERLEUKIN 11;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANOREXIA; ARTHRALGIA; ATHEROSCLEROSIS; BACTERIAL INFECTION; BLEEDING; BLOOD TRANSFUSION REACTION; BONE DEFECT; BONE MARROW DEPRESSION; BRAIN INFARCTION; BREAST CANCER; CARDIOMEGALY; CLINICAL TRIAL; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FLUID RETENTION; GENE LOCATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; INFECTION; KIDNEY DISEASE; LOW DRUG DOSE; LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PAPILLEDEMA; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REFRACTORY THROMBOCYTOPENIA; REVIEW; SIDE EFFECT; SOLID TUMOR; SYNCOPE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; UREMIA; VIRUS INFECTION; BIOLOGICAL MODEL; BONE MARROW DISEASE; CHEMICALLY INDUCED DISORDER; NEOPLASM; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; BONE MARROW DISEASES; HUMANS; INTERLEUKIN-11; MODELS, BIOLOGICAL; NEOPLASMS; PLATELET TRANSFUSION; THROMBOCYTOPENIA;

EID: 34247209644     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600909115     Document Type: Review

References (29)

1. Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J. and Hart, R. D. (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med, 330, pp. 1253-1259.
2. Savarese, D. M., Hsieh, C. and Stewart, F. M. (1997) Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol, 15, pp. 2981-2995.
3. Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M. and Brambilla, C. (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med, 332, pp. 901-906.
4. Wallace, E. L., Churchill, W. H., Surgenor, D. M., Cho, G. and McGurk, S. (1995) Collection and transfusion of blood and blood components in the United States, 1992. Transfusion, 35, pp. 802-812.
5. Sweeney, J. and Headon, A. (1995) Medical Intelligence Unit: Clinical Benefits of Leukodepleted Blood Products. Book, R. G. Landes, Austin, TX
6. Cairo, M. S. (2000) Dose reductions and delays: Limitations of myelosuppressive chemotherapy. Oncology (Williston Park), 14, pp. 21-31.
7. Paul, S. R., Bennett, F., Calvetti, J. A., Kelleher, K., Wood, C. R. and O'Hara Jr, R. M. (1990) Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA, 87, pp. 7512-7516.
8. Musashi, M., Yang, Y. C., Paul, S. R., Clark, S. C., Sudo, T. and Ogawa, M. (1991) Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Natl Acad Sci USA, 88, pp. 765-769.
9. Hirayama, F., Shih, J. P., Awgulewitsch, A., Warr, G. W., Clark, S. C. and Ogawa, M. (1992) Clonal proliferation of murine lymphohemopoietic progenitors in culture. Proc Natl Acad Sci USA, 89, pp. 5907-5911.
10. Teramura, M., Kobayashi, S., Hoshino, S., Oshimi, K. and Mizoguchi, H. (1992) Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood, 79, pp. 327-331.
11. Bruno, E., Briddell, R. A., Cooper, R. J. and Hoffman, R. (1991) Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells. Exp Hematol, 19, pp. 378-381.
12. Williams, D. A. (1997) Interleukin-11: Review of molecular, cell biology, and clinical use. Blood, 89, pp. 3897-3908.
13. Chang, M., Suen, Y., Meng, G., Buzby, J. S., Bussel, J. and Shen, V. (1996) Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: Insight into the regulation of platelet production. Blood, 88, pp. 3354-3362.
14. Neben, S., Donaldson, D., Sieff, C., Mauch, P., Bodine, D. and Ferrara, J. (1994) Synergistic effects of interleukin-11 with other growth factors on the expansion of murine hematopoietic progenitors and maintenance of stem cells in liquid culture. Exp Hematol, 22, pp. 353-359.
15. Goldman, S., Loebelanz, J., McCarthy, K., Hayes, L., Neben, T. and Stoudemire, J. (1991) Recombinant human interleukin-11 (rh-IL-11) stimulates megakaryocyte maturation and increase in peripheral platelet number in vivo. Blood, 78, p. 518A.
16. Gordon, M. S., McCaskill-Stevens, W. J., Battiato, L. A., Loewy, J., Loesch, D. and Breeden, E. (1996) A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood, 87, pp. 3615-3624.
17. Orazi, A., Cooper, R. J., Tong, J., Gordon, M. S., Battiato, L. and Sledge Jr, G. W. (1996) Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow. Exp Hematol, 24, pp. 1289-1297.
18. Isaacs, C., Robert, N. J., Bailey, F. A., Schuster, M. W., Overmoyer, B. and Graham, M. (1997) Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol, 15, pp. 3368-3377.
19. Tepler, I., Elias, L., Smith II, J. W., Hussein, M., Rosen, G. and Chang, A. Y. (1996) A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood, 87, pp. 3607-3614.
20. Cairo, M. S., Davenport, V., Bessmertny, O., Goldman, S. C., Berg, S. L. and Kreissman, S. G. (2005) Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: A clinical, haematological and biological study. Br J Haematol, 128, pp. 49-58.
21. Cripe, L. D., Rader, K., Tallman, M. S., Gordon, M. S., Paietta, E. and Bennett, J. (2006) Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997. Leuk Res, 30, pp. 823-827.
22. Matthews, J. P., Bishop, J. F., Young, G. A., Juneja, S. K., Lowenthal, R. M. and Garson, O. M. (2001) Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia. Br J Haematol, 113, pp. 727-736.
23. Mitus, A. J., Miller, K. B., Schenkein, D. P., Ryan, H. F., Parsons, S. K. and Wheeler, C. (1995) Improved survival for patients with acute myelogenous leukemia. J Clin Oncol, 13, pp. 560-569.
24. Antin, J. H., Smith, B. R., Holmes, W., David, R. N. and Rosenthal, S. (1988) Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure. Behring Inst Mitt, pp. 149-153.
25. Bessho, M., Hirashima, K., Asano, S., Ikeda, Y., Ogawa, N. and Tomonaga, M. (1997) Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: A multicenter randomized controlled study. Multicenter Study Group. Eur J Haematol, 58, pp. 265-272.
26. Saba, H. I. (1996) Myelodysplastic syndromes in the elderly: The role of growth factors in management. Leuk Res, 20, pp. 203-219.
27. Bussel, J. B., Mukherjee, R. and Stone, A. J. (2001) A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol, 66, pp. 172-177.
28. Kurzrock, R., Cortes, J., Thomas, D. A., Jeha, S., Pilat, S. and Talpaz, M. (2001) Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol, 19, pp. 4165-4172.
29. Tsimberidou, A. M., Giles, F. J., Khouri, I., Bueso-Ramos, C., Pilat, S. and Thomas, D. A. (2005) Low-dose interleukin-11 in patients with bone marrow failure: Update of the MD. Anderson Cancer Center experience. Ann Oncol, 16, pp. 139-145.